ELUTIA INC. (ELUT): Results of Operations and Financial Condition
ELUTIA INC. (ELUT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Elutia Secures Up to $26 Million to Fund NXT-41x Through Commercial Launch; Reports Second Quarter 2026 Results Independent Blinded Survey of 50 Plastic Surgeons Validates Demand; NXT-41 and NXT-41x Remain On-Track ● Funded through launch: secured up to $26 mil
How this was made
The 30-second read
Why it matters
The filing combines (1) a new capital package without an equity offering, (2) updated/confirmed FDA clearance expectations, and (3) Q2 financial results with margin improvement and operating expense trends, which together can re-rate ELUT’s probability-weighted path to commercialization.
Market read
Traders can update ELUT’s dilution risk and milestone probability based on the disclosed $26 million funding package and the reiterated FDA clearance schedule.
What to watch
The release highlights a manufacturing gross-margin target (>80%) but does not quantify current scale performance; execution risk around the automated drug-coating system could matter as launch approaches.
Elutia Secures Up to $26 Million to Fund NXT-41x Through Commercial Launch; Reports Second Quarter 2026 Results
GAAP gross margin improved to 59.6% and total operating expenses declined to $9.4 million, but net sales fell to $2.4 million, adjusted EBITDA loss widened to $4.6 million, and execution remains dependent on regulatory clearances, divestiture proceeds and contingent financing.
Key metrics
as reported| Metric | Value | q/q | y/y |
|---|---|---|---|
| Net sales, three months ended June 30, 2026GAAP | $ 2,427 | – | – |
| Cost of goods sold, three months ended June 30, 2026GAAP | 980 | – | – |
| Gross profit, three months ended June 30, 2026GAAP | 1,447 | – | – |
| Gross margin, three months ended June 30, 2026GAAP | 59.6% | – | – |
| Adjusted gross profit, three months ended June 30, 2026non-GAAP | $ 1,717 | – | – |
| Adjusted gross margin, three months ended June 30, 2026non-GAAP | 70.7% | – | – |
| Sales and marketing expense, three months ended June 30, 2026GAAP | 1,366 | – | – |
| General and administrative expense, three months ended June 30, 2026GAAP | 3,454 | – | – |
| Research and development expense, three months ended June 30, 2026GAAP | 2,527 | – | – |
| Litigation costs, net, three months ended June 30, 2026GAAP | 2,057 | – | – |
| Total operating expenses, three months ended June 30, 2026GAAP | 9,404 | – | – |
| Loss from operations, three months ended June 30, 2026GAAP | (7,957) | – | – |
| Interest income, net, three months ended June 30, 2026GAAP | (35) | – | – |
| Other (income) expense, net, three months ended June 30, 2026GAAP | (284) | – | – |
| Loss before provision for income taxes, three months ended June 30, 2026GAAP | (7,638) | – | – |
| Provision for income taxes, three months ended June 30, 2026GAAP | 8 | – | – |
| Net loss from continuing operations, three months ended June 30, 2026GAAP | (7,646) | – | – |
| Loss income from discontinued operations, three months ended June 30, 2026GAAP | — | – | – |
| Net loss, three months ended June 30, 2026GAAP | $ (7,646) | – | – |
| Net loss per share, basic, three months ended June 30, 2026GAAP | $ (0.17) | – | – |
| Net loss per share, diluted, three months ended June 30, 2026GAAP | $ (0.17) | – | – |
| Weighted average common shares outstanding, basic, three months ended June 30, 2026GAAP | 44,223,722 | – | – |
| Weighted average common shares outstanding, diluted, three months ended June 30, 2026GAAP | 44,223,722 | – | – |
| EBITDA, three months ended June 30, 2026non-GAAP | (7,325) | – | – |
| Adjusted EBITDA, three months ended June 30, 2026non-GAAP | $ (4,589) | – | – |
| Net sales, six months ended June 30, 2026GAAP | $ 5,541 | – | – |
| Gross profit, six months ended June 30, 2026GAAP | 3,249 | – | – |
| Gross margin, six months ended June 30, 2026GAAP | 58.6% | – | – |
| Adjusted gross profit, six months ended June 30, 2026non-GAAP | $ 3,789 | – | – |
| Adjusted gross margin, six months ended June 30, 2026non-GAAP | 68.4% | – | – |
| Total operating expenses, six months ended June 30, 2026GAAP | 17,554 | – | – |
| Loss from operations, six months ended June 30, 2026GAAP | (14,305) | – | – |
| Net loss from continuing operations, six months ended June 30, 2026GAAP | (15,540) | – | – |
| Loss income from discontinued operations, six months ended June 30, 2026GAAP | 425 | – | – |
| Net loss, six months ended June 30, 2026GAAP | $ (15,115) | – | – |
| Net loss per share, basic, six months ended June 30, 2026GAAP | $ (0.35) | – | – |
| Net loss per share, diluted, six months ended June 30, 2026GAAP | $ (0.35) | – | – |
| Adjusted EBITDA, six months ended June 30, 2026non-GAAP | $ (8,998) | – | – |
| Cash and cash equivalents at June 30, 2026GAAP | $ 19,896 | – | – |
4Q 2026 / 1H 2027 / 2H 2027 / 2028 outlook
- NoteNXT-41 FDA clearance decision expected in 4Q 2026
- NoteNXT-41x FDA clearance decision expected in 1H 2027
- NoteNXT-41x commercial soft launch expected in 2H 2027
- NoteNXT-41x full commercial launch expected in 2028
- NoteSimpliDerm business divestiture closing expected in 3Q 2026
- NotePotential cardiovascular business transaction expected in 2H 2026
- Note$8 million BioEnvelope escrow release expected in 4Q 2026
- NoteThe system is designed to support target gross margins in excess of 80% at scale.
What drove it
- Overall net sales decreased because of a $0.7 million reduction in SimpliDerm revenue due to a production disruption with the product’s contract manufacturer, partially offset by a $0.4 million increase in Cardiovascular revenue due to the transition back to direct sales.
- Gross margin on a GAAP basis was 59.6%, compared to 52.9%, while adjusted gross margin was 70.7%, compared to 62.7%.
- Total operating expenses decreased due to a $1.9 million reduction in net litigation costs, partially offset by a $1.5 million increase in research and development expense supporting the NXT-41 and NXT-41x programs.
- An independent blinded survey of 50 board-certified plastic and reconstructive surgeons found that 96% expressed interest in incorporating NXT-41x into their general practice and 92% indicated willingness to approach their hospital value analysis committee in support of NXT-41x.
- Elutia completed installation and operational qualification of its automated drug-coating system for commercial manufacturing.
Concerns
- Overall net sales were $2.4 million, compared to $2.7 million, following a production disruption with SimpliDerm’s contract manufacturer.
- Adjusted EBITDA was a loss of $4.6 million, compared to a loss of $3.0 million.
- Net loss from continuing operations was $7.6 million, compared to $7.1 million.
- The additional $5 million under the Avenue Capital loan facility is available following NXT-41x FDA clearance.
- Up to $3 million of SimpliDerm consideration consists of contingent technology transfer and commercial milestone payments over the 18 months following closing.
- The Company identifies risks related to FDA authorization, credit-facility covenants, indebtedness, the SimpliDerm sale, a potential Cardiovascular transaction, litigation, third-party suppliers and manufacturers, and Nasdaq listing compliance.
What to watch
- SimpliDerm business divestiture closing expected in 3Q 2026.
- Potential cardiovascular business transaction expected in 2H 2026.
- $8 million BioEnvelope escrow release expected in 4Q 2026.
- NXT-41 FDA clearance decision expected in 4Q 2026.
- NXT-41x FDA clearance decision expected in 1H 2027.
- NXT-41x commercial soft launch expected in 2H 2027.
- NXT-41x full commercial launch expected in 2028.
- The availability of the additional $5 million tranche under the Avenue Capital financing following NXT-41x FDA clearance.
Balance sheet and cash flow
- Cash and cash equivalents were $ 19,896 at June 30, 2026, compared to $ 36,350 at December 31, 2025.
- Accounts receivable, net were 1,438 at June 30, 2026, compared to 1,734 at December 31, 2025.
- Inventory was 2,649 at June 30, 2026, compared to 2,617 at December 31, 2025.
- Total current assets were 37,215 at June 30, 2026, compared to 55,818 at December 31, 2025.
- Total assets were $ 43,649 at June 30, 2026, compared to $ 62,350 at December 31, 2025.
- Current portion of revenue interest obligation was 6,412 at June 30, 2026, compared to 4,400 at December 31, 2025.
- Long-term revenue interest obligation was — at June 30, 2026, compared to 2,828 at December 31, 2025.
- Total liabilities were 27,903 at June 30, 2026, compared to 34,678 at December 31, 2025.
- Total stockholders' equity was 15,746 at June 30, 2026, compared to 27,672 at December 31, 2025.
- The Company secured up to $26 million of additional capital, including a $15 million credit facility and up to $11 million from the SimpliDerm divestiture.
- The $15 million credit facility includes $10 million funded at closing and an additional $5 million available following NXT-41x FDA clearance.
- The Company anticipates receiving the full $8 million held in escrow from the 2025 divestiture of the BioEnvelope business, with release expected in the fourth quarter of this year.
Analysis
Elutia reported $2.4 million of second-quarter net sales, compared to $2.7 million. Management attributed the decline to a $0.7 million reduction in SimpliDerm revenue following a production disruption at its contract manufacturer, partially offset by a $0.4 million increase in Cardiovascular revenue as the business transitioned back to direct sales. The release did not report actual revenue by either business, so the segment mix cannot be quantified beyond those stated revenue movements.
Profitability showed better gross-margin performance but continued operating losses. GAAP gross margin rose to 59.6% from 52.9%, and adjusted gross margin rose to 70.7% from 62.7%. Total operating expenses declined to $9.4 million from $9.8 million as lower net litigation costs more than offset higher research and development spending. Research and development expense was $2.5 million versus $1.0 million, reflecting investment in NXT-41 and NXT-41x. Loss from operations was $8.0 million versus $8.4 million, while net loss from continuing operations increased to $7.6 million from $7.1 million.
The principal earnings-quality pressure was the adjusted EBITDA loss of $4.6 million, compared with a $3.0 million loss. Cash and cash equivalents were $19.9 million at June 30, 2026, compared with $36.4 million at December 31, 2025. Elutia cited up to $26 million of additional capital from a credit facility and the planned SimpliDerm divestiture, plus an anticipated $8 million BioEnvelope escrow release. However, $5 million of credit-facility availability depends on NXT-41x FDA clearance, and up to $3 million of SimpliDerm consideration is contingent.
The company is focusing the organization on NXT-41x, with SimpliDerm divestiture closing expected in 3Q 2026 and the Cardiovascular strategic process continuing. Its blinded surgeon survey supports stated interest in NXT-41x, while management also completed installation and operational qualification of an automated drug-coating system designed to support target gross margins in excess of 80% at scale. The near-term milestones are the anticipated BioEnvelope escrow release and NXT-41 clearance in 4Q 2026, followed by anticipated NXT-41x clearance in 1H 2027, a soft launch in 2H 2027 and a full commercial launch in 2028.
The quarter therefore combines improved gross margin, lower operating expenses and progress toward the NXT-41x launch with a sales decline, increased continuing-operations net loss and a wider adjusted EBITDA loss. Financial and operating execution now centers on completion of planned transactions, regulatory timing, access to conditional capital and eventual conversion of reported surgeon interest into commercial adoption.
Management, verbatim
We believe we are now funded through the anticipated clearance and full commercial launch of NXT-41x, our antibiotic-eluting biomatrix for use in plastic and reconstructive surgical procedures. And we did it without an equity offering.
Dr. Randy Mills, Chief Executive Officer of Elutia
As we approach anticipated FDA clearance decisions and launch, surgeon interest in NXT-41x has exceeded our expectations.
Dr. Randy Mills, Chief Executive Officer of Elutia
Not in the filing
stated, not guessed- Prior-quarter comparisons for reported operating metrics
- Reported revenue by SimpliDerm segment
- Reported revenue by Cardiovascular segment
- Segment revenue growth percentages
- GAAP operating margin
- Non-GAAP earnings or loss per share
- Operating cash flow
- Free cash flow
- Capital expenditures
- Share repurchases
- Dividend payments
- Traditional debt balance or net debt
- Revenue guidance
- Gross-margin guidance
- Operating-expense guidance
- Tax-rate guidance
- Prior-quarter outlook for comparison
AlphaAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
Elutia is advancing NXT-41 and NXT-41x, antibiotic-eluting biomatrix technologies, while reshaping its portfolio via divestitures (SimpliDerm, BioEnvelope, and a continuing Cardiovascular process).
Ticker impact
Elutia secured up to $26 million without an equity offering and reiterated FDA clearance timing for NXT-41 (4Q26) and NXT-41x (1H27).
Bias toward upside on any market read-through to higher probability of NXT-41x clearance and reduced dilution risk, with volatility around FDA milestone headlines.
The 8-K discloses new financing terms (credit facility plus divestiture proceeds/escrow) and specific regulatory timing, both of which can change probability-weighted outcomes and dilution expectations.
Market effects
Reinforces the market narrative that drug-eluting biomatrix platforms can attract non-dilutive funding tied to FDA milestones.
Limited, primarily company-specific (Gaithersburg, MD) with no broader regional macro signal.
Low; the story is US FDA-timing and company financing focused.
Counterpoint
Survey-driven demand validation may not translate into payer coverage, reimbursement, or real-world adoption at scale, so clearance timing may be the only tradable catalyst.
Key entities
- companyElutia Inc.
Nasdaq-listed drug-eluting biomatrix developer; subject of the 8-K with financing, FDA timing, and Q2 results.
- productNXT-41x
Antibiotic-eluting biomatrix for plastic and reconstructive surgical procedures; FDA clearance expected in 1H 2027.
- regulatorFDA
Regulatory body for clearance decisions referenced for NXT-41 (4Q26) and NXT-41x (1H27).
- transactionSimpliDerm divestiture
Definitive agreement to sell SimpliDerm for up to $11 million, with closing expected in 3Q 2026.
